Description
SR1001 is an inverse agonist at RORα/γ receptors that prevents Th17 cell development, differentiation, and function. It exhibits anti-diabetic, anti-inflammatory, immunomodulatory, and antidepressant activities. In animal models of diabetes, SR1001 decreases diabetes incidence and insulitis, suppresses expression of pro-inflammatory cytokines, and increases levels of CD4+, Foxp3+ Treg cells. In animal models of depression-like behaviors, SR1001 decreases Th17-dependent learned helplessness.